SG11201907869VA - Medicament for malignant tumor treatment - Google Patents

Medicament for malignant tumor treatment

Info

Publication number
SG11201907869VA
SG11201907869VA SG11201907869VA SG11201907869VA SG11201907869VA SG 11201907869V A SG11201907869V A SG 11201907869VA SG 11201907869V A SG11201907869V A SG 11201907869VA SG 11201907869V A SG11201907869V A SG 11201907869VA SG 11201907869V A SG11201907869V A SG 11201907869VA
Authority
SG
Singapore
Prior art keywords
malignant tumor
medicament
determination
immune system
expression pattern
Prior art date
Application number
SG11201907869VA
Inventor
Wolfgang Würfel
Original Assignee
Intellexon Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellexon Gmbh filed Critical Intellexon Gmbh
Publication of SG11201907869VA publication Critical patent/SG11201907869VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Medicament for Malignant Tumor Treatment Methods for providing a medicament for the treatment of a malignant tumor taking into account the individually associated immune system, and also antibodies provided thereby in the use thereof, are disclosed, wherein the individual communication structure between the malignant tumor and the immune system is ascertained by determination of an expression pattern of embryonic HLA groups and by determination of a receptor type present on/in immunocompetent cells, and antibodies are provided of the type which specifically bond as ligands to the at least one determined receptor type and, as a result block or mask the receptor in such a manner that the at least one portion of the expression pattern cannot find their or can only bind there with lower action, but themselves do not inhibit the associated immunocompetent cell. Fig. 2
SG11201907869VA 2017-02-27 2018-02-22 Medicament for malignant tumor treatment SG11201907869VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017001875.8A DE102017001875A1 (en) 2017-02-27 2017-02-27 Drug for malignant treatment
PCT/EP2018/054339 WO2018153956A1 (en) 2017-02-27 2018-02-22 Medicament for malignant tumor treatment

Publications (1)

Publication Number Publication Date
SG11201907869VA true SG11201907869VA (en) 2019-09-27

Family

ID=61283222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907869VA SG11201907869VA (en) 2017-02-27 2018-02-22 Medicament for malignant tumor treatment

Country Status (9)

Country Link
US (1) US20190376968A1 (en)
EP (1) EP3586132B1 (en)
JP (2) JP2020510695A (en)
CA (1) CA3054495A1 (en)
DE (1) DE102017001875A1 (en)
ES (1) ES2951762T3 (en)
IL (1) IL268897A (en)
SG (1) SG11201907869VA (en)
WO (1) WO2018153956A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070286A2 (en) * 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a
DE102011111631A1 (en) 2011-08-25 2013-02-28 Wolfgang Würfel Process for the preparation of medicaments for combating tumors
US20160045594A1 (en) 2013-03-27 2016-02-18 Fred Hutchinson Cancer Research Center Directed immune stimulation
RU2017105425A (en) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк ANTIBODY COMBINATIONS AGAINST CD94 / NKG2A AND / OR CD94 / NKG2B AND VACCINES
KR20230088521A (en) * 2014-09-16 2023-06-19 이나뜨 파르마 에스.에이. Neutralization of inhibitory pathways in lymphocytes
EP3659625A1 (en) * 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017025962A1 (en) 2015-08-10 2017-02-16 Tel Hashomer Medical Research, Infrastructure And Services Ltd Prediction of response to immunotherapy based on tumor biomarkers

Also Published As

Publication number Publication date
EP3586132C0 (en) 2023-06-07
DE102017001875A1 (en) 2018-08-30
CA3054495A1 (en) 2018-08-30
US20190376968A1 (en) 2019-12-12
IL268897A (en) 2019-10-31
ES2951762T3 (en) 2023-10-24
EP3586132A1 (en) 2020-01-01
EP3586132B1 (en) 2023-06-07
JP2023027134A (en) 2023-03-01
WO2018153956A1 (en) 2018-08-30
JP2020510695A (en) 2020-04-09

Similar Documents

Publication Publication Date Title
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
CR20190477A (en) Fc-optimized anti-cd25 for tumour specific cell depletion
PH12018500394A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
SA518390903B1 (en) Novel anti-PD-1 antibodies
CL2015002522A1 (en) Compositions and methods to activate "interferon gene stimulator" - dependent signaling.
MX2020005463A (en) Cd47 antibodies and uses thereof for treating cancer.
MX2019008503A (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof.
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
MX2020011788A (en) Trifunctional t cell-antigen coupler and methods and uses thereof.
MX2019000643A (en) Chimeric antigen receptors and methods for use.
NZ719840A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2017004691A (en) Cd73 blockade.
MX2016010345A (en) Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells.
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
MX2020009439A (en) Intracellular delivery of biomolecules to modify immune response.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2020010399A (en) 3-epimerase.
MX2019006527A (en) Modulators of complement activity.
MX2019006286A (en) Methods for determining car-t cells dosing.
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
MX2019010382A (en) Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy.
MX2021008605A (en) Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers.
MX2020005640A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer.
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
MX2022006073A (en) Methods of use of anti-trem2 antibodies.